Alpha Tau Medical (DRTS) had its "neutral" rating reaffirmed by Piper Sandler. They now have a $5.00 price target on the stock.
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
Alpha Tau Medical (NASDAQ:DRTS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead